Table 1 Published cases of omalizumab use in urticarial vasculitis
From: Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
References | Details | Age (years) | Complement levels | Systemic symptoms | Omalizumab | Effect of omalizumab | |
|---|---|---|---|---|---|---|---|
Frequency (weeks) | Dose (mg) | ||||||
Del Pozo et al. [7] | Female with systemic lupus erythematosus (SLE) | 51 | Normal C3, low C4 | Arthralgia (SLE) | Unknown, based on weight and IgE level | Partial resolution after 3 × doses | |
Varricchi et al. [8] | Female with Churg-Strauss syndrome (CSS) | 44 | Unknown | Asthma (CSS) | 2 | 300 | Complete, immediate resolution |
Diez et al. [2] | Female | 51 | Normal | No | 4 | 150 | Complete resolution after 4–5 doses, relapse on cessation |
| Â | Female | 54 | Unknown | No | 4 | 150 | |
| Â | Female | 28 | Normal | No | 4 | 300 | Complete immediate resolution, relapse on cessation |
Sussman et al. [3] | Unspecified adult | Â | Unknown | Unknown | 2 | 150 | Complete resolution |
Kai et al. [6] | Unspecified adult | Â | Normal | No | 4 | 150 | Response, relapse on cessation |
Ghazanfar et al. [4] | Male | 68 | Unknown | No | 4 | 300 | Complete resolution |
Aurich et al. [9] | Female | 36 | Low C3 and C4 | Nephrotic syndrome | 4 | 300–600 | No response over 19 months |
Nucera et al. [10] | Female | 47 | Low C3 (0.17Â g/L), normal C1q and anti C1q | No major organ dysfunction but arthralgia/abdominal pain | 4 | 300 | Complete resolution after 2nd injection. Complement levels returned to normal. Relapse on treatment cessation |